Gainers

• Kiniksa Pharmaceuticals (NASDAQ:KNSA) shares rose 23.1% to $89.86 during Tuesday's regular session. The market value of their outstanding shares is at $5.6 billion. As per the press release, Q3 earnings came out today.
• PDS Biotechnology (NASDAQ:PDSB) shares moved upwards by 18.77% to $1.26. The market value of their outstanding shares is at $77.1 million.
• Aardvark Therapeutics (NASDAQ:AARD) shares rose 17.59% to $1.27. The company's market cap stands at $23.6 million.
• Moleculin Biotech (NASDAQ:MBRX) stock increased by 17.43% to $8.32. The market value of their outstanding shares is at $7.2 million.
• Pomdoctor (NASDAQ:POM) shares rose 16.81% to $1.32. The company's market cap stands at $3.1 million.
• Zura Bio (NASDAQ:ZURA) shares rose 16.57% to $4.15. The market value of their outstanding shares is at $341.1 million. As per the news, the Q3 earnings report came out today.

Losers

• Baird Medical Investment (NASDAQ:BDMD) shares fell 41.3% to $0.25 during Tuesday's regular session. The company's market cap stands at $13.7 million.
• SciSparc (NASDAQ:SPRC) shares fell 35.35% to $0.83.
• Artiva Biotherapeutics (NASDAQ:ARTV) shares fell 31.25% to $4.24. The market value of their outstanding shares is at $301.1 million.
• Actuate Therapeutics (NASDAQ:ACTU) shares declined by 25.21% to $0.39. The market value of their outstanding shares is at $12.6 million.
• Universe Pharmaceuticals (NASDAQ:UPC) shares fell 23.31% to $2.21. The market value of their outstanding shares is at $14.4 million.
• Imunon (NASDAQ:IMNN) shares declined by 22.12% to $0.96. The company's market cap stands at $6.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.